AN2 Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
AN2 Therapeutics, Inc. (ANTX) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of -$300.00 thousand for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-03-17
- AN2 Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-12-31 was $0.00.
- AN2 Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-09-30 was $100.00K.
- AN2 Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-06-30 was -$100.00K, a 200.00% decline year-over-year.
- AN2 Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-03-31 was -$200.00K, a 200.00% decline year-over-year.
- AN2 Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2024 was -$200.00K.
- AN2 Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2023 was -$600.00K.
- AN2 Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2022 was -$300.00K.
- AN2 Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2021 was -$30.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month as first filed | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month as first filed | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-06-30 | -$300.00K 10-Q · filed 2025-08-12 | ||||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $100.00K derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | -$200.00K 10-K · filed 2026-03-17 | $200.00K 10-K · filed 2025-03-25 | ||
| 2024-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | -$200.00K 10-Q · filed 2025-11-12 | -$1.10M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | -$100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$300.00K 10-Q · filed 2025-08-12 | -$1.20M derived: sum of 3 quarters · filed 2025-08-12 | -$1.20M derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2024-03-31 | -$200.00K 10-Q · filed 2025-05-13 | -$1.10M derived: sum of 2 quarters · filed 2025-05-13 | -$1.10M derived: sum of 3 quarters · filed 2025-05-13 | -$1.00M derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | -$900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$900.00K derived: sum of 2 quarters · filed 2025-03-25 | -$800.00K derived: sum of 3 quarters · filed 2025-03-25 | -$600.00K 10-K · filed 2025-03-25 | $600.00K 10-K · filed 2024-03-29 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $100.00K derived: sum of 2 quarters · filed 2024-11-13 | $300.00K 10-Q · filed 2024-11-13 | $500.00K derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $300.00K 10-Q · filed 2024-08-13 | $500.00K derived: sum of 3 quarters · filed 2024-08-13 | $300.00K derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $200.00K 10-Q · filed 2024-05-14 | $400.00K derived: sum of 2 quarters · filed 2024-05-14 | $200.00K derived: sum of 3 quarters · filed 2024-05-14 | $0.00 derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | -$200.00K derived: sum of 3 quarters · filed 2024-03-29 | -$300.00K 10-K · filed 2024-03-29 | |||
| 2022-09-30 | -$200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$400.00K derived: sum of 2 quarters · filed 2023-11-09 | -$500.00K 10-Q · filed 2023-11-09 | $500.00K 10-Q · filed 2022-11-09 | -$530.00K derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | -$200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$300.00K 10-Q · filed 2023-08-10 | $300.00K 10-Q · filed 2022-08-11 | -$330.00K derived: sum of 3 quarters · filed 2023-08-10 | -$330.00K derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | -$100.00K 10-Q · filed 2022-05-10 | -$130.00K derived: sum of 2 quarters · filed 2023-03-29 | -$130.00K derived: sum of 3 quarters · filed 2023-03-29 | -$130.00K derived: sum of 4 quarters · filed 2023-03-29 | |||
| 2021-12-31 | -$30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$30.00K derived: sum of 2 quarters · filed 2023-03-29 | -$30.00K derived: sum of 3 quarters · filed 2023-03-29 | -$30.00K 10-K · filed 2023-03-29 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | |||||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |